Point72 Asset Management L.P. Buys New Position in Voyager Therapeutics Inc (VYGR)

Point72 Asset Management L.P. bought a new stake in shares of Voyager Therapeutics Inc (NASDAQ:VYGR) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 130,900 shares of the company’s stock, valued at approximately $2,695,000. Point72 Asset Management L.P. owned 0.42% of Voyager Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Bank of New York Mellon Corp increased its stake in shares of Voyager Therapeutics by 20.9% during the second quarter. Bank of New York Mellon Corp now owns 53,225 shares of the company’s stock valued at $477,000 after buying an additional 9,207 shares during the period. Vanguard Group Inc. increased its stake in shares of Voyager Therapeutics by 3.2% during the second quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock valued at $3,860,000 after buying an additional 13,194 shares during the period. Wells Fargo & Company MN increased its stake in shares of Voyager Therapeutics by 9.3% during the second quarter. Wells Fargo & Company MN now owns 91,384 shares of the company’s stock valued at $819,000 after buying an additional 7,807 shares during the period. Citadel Advisors LLC purchased a new position in shares of Voyager Therapeutics during the third quarter valued at approximately $5,155,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in shares of Voyager Therapeutics during the third quarter valued at approximately $1,122,000. 35.97% of the stock is currently owned by hedge funds and other institutional investors.

VYGR has been the topic of several research analyst reports. Wedbush reissued a “positive” rating and set a $31.00 target price (down from $36.00) on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Canaccord Genuity initiated coverage on Voyager Therapeutics in a research note on Friday, October 27th. They set a “buy” rating and a $35.00 target price on the stock. Zacks Investment Research cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Cowen reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Finally, ValuEngine cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $26.90.

In related news, insider Bernard Ravina sold 5,490 shares of the company’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $13.26, for a total value of $72,797.40. Following the sale, the insider now directly owns 16,473 shares of the company’s stock, valued at $218,431.98. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders sold 21,960 shares of company stock worth $370,850. 8.00% of the stock is owned by insiders.

Shares of Voyager Therapeutics Inc (VYGR) opened at $15.74 on Thursday. Voyager Therapeutics Inc has a 12 month low of $8.10 and a 12 month high of $25.99.

TRADEMARK VIOLATION NOTICE: “Point72 Asset Management L.P. Buys New Position in Voyager Therapeutics Inc (VYGR)” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://sportsperspectives.com/2017/12/21/point72-asset-management-l-p-buys-new-position-in-voyager-therapeutics-inc-vygr.html.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply